Shionogi & Co., Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.
The company’s product portfolio spans both established and innovative therapies. Shionogi markets cefiderocol (Fetroja) for complicated urinary tract infections, an investigational oral antiviral for COVID-19, and a range of influenza treatments. It also collaborates with international partners on HIV integrase inhibitors and oncology agents, leveraging strategic alliances to accelerate global development and distribution.
Headquartered in Osaka, Shionogi maintains research facilities and subsidiaries across Asia, North America and Europe. Its network of laboratories focuses on discovery science, translational research and clinical development, while manufacturing sites in Japan and abroad ensure supply chain resilience and regulatory compliance in multiple regions.
Governed by a board of directors and led by a President & Representative Director, Shionogi continues to invest heavily in R&D, with a pipeline targeting antimicrobial resistance, metabolic diseases and novel immunotherapies. Its unsponsored American depositary receipt trades on the OTC Market under the ticker SGIOY, providing U.S. investors access to its evolving business.
